This observation may be attributed to a deficiency or dysfunction of ADAMTS-13 activity detected in the plasma of patients with metastatic cancer, or the augmented VWF secretion from the tumour microenvironment [54, 72]. The gene discussed is ADAMTS13; the disease is metastatic malignant neoplasm.